Acer Therapeutics Inc

Acer Therapeutics — Investor Presentation (March 2023)

25 slides from Acer Therapeutics's investor presentation, Mar 27, 2023

  1. Slide 1: Corporate Presentation

    Corporate Presentation March 27, 2023 Exhibit 99.2

  2. Slide 2: Forward-looking statements

    Forward-looking statements This presentation contains “forward-looking statements” that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in

  3. Slide 3: The Acer story: mission, difference, goal

    To provide transformative treatments with a human touch to underserved or overlooked patients with rare and life-threatening diseases We identify and develop treatments where science can be applied in new ways for use in diseases with high unmet need To develop treatments quickly and more efficientl

  4. Slide 4: Acer Management team

    Acer Management team Chris schelling Chief Executive officer & Founder Adrian quartel, md Chief medical officer Harry palmin Chief financial officer Bernie paul Chief people officer Don joseph, Jd Chief legal officer John klopp Chief technical officer Tanya hayden Chief operating officer Jeff davis

  5. Slide 5: Pipeline and expected milestones

    Program Indication Phase 1 Phase 2 Phase 3 Approved Expected Milestones Urea Cycle Disorders1 Approved in US; drug in channel anticipated July 2023$ EDSIVO™ (celiprolol) Vascular Ehlers-Danlos Syndrome (COL3A1+) Q4 2023: Full trial enrollment$ ACER-801 (osanetant) Menopausal-related Vasomotor Sympto

  6. Slide 6: OLPRUVA (sodium phenylbutyrate) for oral suspension

    Full Prescribing Information: https://www.acertx.com/OLPRUVA/PI.pdf OLPRUVATM (sodium phenylbutyrate) for oral suspension

  7. Slide 7: UCDs: Disease Overview

    UCDs: DISEASE Overview Urea Cycle Disorders (UCDs) are a group of rare, genetic disorders caused by mutations that result in a deficiency of one of the six enzymes or two transporters of the urea cycle These enzymes are responsible for removing ammonia from the bloodstream Reproduced from: http://up

  8. Slide 8: UCDs: Mechanism of action

    UCDs: Mechanism of action Nitrogen Binding Agents Alternative pathway treatment diverts nitrogen from the urea cycle to alternate routes of excretion Nitrogen binding agents, containing phenylbutyrate, are all metabolized to phenylacetate (PAA) PAA is the active moiety – it combines with glutamine,

  9. Slide 9: Novel Formulation

    NOVEL Formulation OLPRUVA™ is a proprietary and novel formulation of NaPB powder that has shown bioequivalence to existing NaPB powder but with a pH-sensitive polymer coating that is designed to minimize dissolution of the coating for up to 5 minutes after preparation1 Polymer Coat (inactive pH-sens

  10. Slide 10: Nitrogen Scavenger Differentiation

    Nitrogen Scavenger Differentiation1 Phenylbutyrate Formulations OLPRUVA™ RAVICTI® BUPHENYL® PHEBURANE® Efficacy / Safety in UCDs ✓ ✓ ✓ ✓ Formulation Dual-coated oral pellets Clear Oily Liquid Powder or Tablets Single-coated oral pellets Palatability Up to 5 minutes Tasteless Bitter Taste Up to 10 se

  11. Slide 11: Commercial Strategy

    Commercial Strategy Significant unmet need and desire for new treatment options OLPRUVA™ is differentiated, dual coated, packaged in portable single dose envelopes Robust patient services program to support patients & caregivers Customized exclusive pharmacy approach to facilitate patient access to

  12. Slide 12: Disrupting an established UCD market in U.S.

    DISRUPTING AN ESTABLISHED UCD MARKET in U.S. Projected Prevalence1 ~ 2,100 Diagnosed Patients2 ~ 1,100 Patients Treated with Phenylbutyrate2 (Ravicti®, Buphenyl®, generics) ~ 800 Market share for nitrogen binding agents2 ~ 80% Ravicti® ~ 20% Buphenyl® or generic NaPB 2021 U.S. Net Revenue3 (Ravicti®

  13. Slide 13: Intellectual property and exclusivity

    Intellectual property and exclusivity Orange Book Listed Patents: US Pat. Nos. 11,154,521 and 11,433,041 directed to formulations/compositions of matter US Pat. No. 11,202,767 directed to methods of use (UCD) Expiration date for OB patents is 10/17/2036 MSUD US Pat. Nos. 9,078,865 and 10,092,532 dir

  14. Slide 14: Lifecycle Opportunities

    Acer intends to explore additional lifecycle opportunities for OLPRUVA™ (sodium phenylbutyrate) in various disorders where proof of concept data exists: Maple Syrup Urine Disease (MSUD) Pyruvate Dehydrogenase Complex Deficiency (PCDC) Rare pediatric epilepsies Various liver disorders Lifecycle Oppor

  15. Slide 15: EDSIVO (celiprolol) for vEDS

    A selective adrenergic modulator (SAM) for the potential treatment of patients with COL3A1-positive vascular Ehlers-Danlos Syndrome (vEDS) (celiprolol) Vascular Ehlers-Danlos Syndrome (vEDS) EDSIVOTM

  16. Slide 16: Vascular Ehlers-Danlos Syndrome epidemiology

    VASCULAR EHLERS-DANLOS SYNDROME EPIDEMIOLOGY Prevalence: Up to 7,500 COL3A1+ vEDS patients in US5 Median US Survival: 51 years of age1 Risk: Arterial rupture or dissection events occur in ~25% of patients before the age of 20, but increase to ~90% of patients by age 401 1 Pepin, et al. Survival is a

  17. Slide 17: BBEST Trial: COL3A1+ Subpopulation

    BBEST Trial: COL3A1+ Subpopulation 76% reduction in the risk of fatal or nonfatal cardiac or arterial events in COL3A1+ EDSIVO™ patients vs. control group over mean follow-up of 47 months 75% reduction in risk of primary (cardiac or arterial events) and secondary (intestinal or uterine rupture) even

  18. Slide 18: Pivotal Phase 3 trial: enrolling patients

    pivotal phase 3 trial: enrolling patients $ Additional capital required to conduct and complete the planned pivotal Phase 3 trial of EDSIVO™ beyond Q4 2022 Decentralized Study of Celiprolol on vEDS-related Event Reduction (DiSCOVER) Trial A Phase 3, U.S.-based, randomized, double-blind, decentralize

  19. Slide 19: ACER-801 (osanetant)

    A novel, non-hormonal, Neurokinin 3 receptor (NK3R) antagonist Acute Stress & PTSD Vasomotor Symptoms Prostate Cancer ACER-801 (osanetant) ACER-801 (osanetant)

  20. Slide 20: VMS: Phase 2a trial

    Endpoints VMS: phase 2a trial Study Population 49 women aged 40-65, who experience moderate to severe hot flashes Primary Endpoints 1) Evaluate safety profile of ACER-801 at different doses 2) Evaluate PK profile of ACER-801 across dose levels Key Secondary Endpoint Evaluate the effect of ACER-801 a

  21. Slide 21: VMS and iVMS

    VMS and ivms Vasomotor symptoms are caused by a disruption in sex hormone signaling in the brain, resulting in menopausal-like symptoms (hot flashes, night sweats, etc.) Disease Overview 50% of women during menopause transition experience mod-severe hot flashes iVMS is a prevalent side-effect of var

  22. Slide 22: ACER-801: Prostate cancer

    ACER-801: prostate cancer EPIDEMIOLOGY Prostate Treatment: 3.25 million men in US3 268,000 newly diagnosed patients with prostate cancer3 Of men who received a diagnosis of prostate cancer from 2003-2005, a total of 43.2% received ADT within 6 months after diagnosis4 Prostate iVMS: 75,000 men in the

  23. Slide 23: Acute stress & PTSD

    acute stress & ptsd EPIDEMIOLOGY PTSD Prevalence: ~12 million adults in US3 ~60% of men and 50% of women experience at least 1 trauma in their lifetime Up to 20% of those who experienced at least one traumatic event will develop PTSD4 Emergency Dept. Visits: ~1/3 of ED visits are for trauma exposure

  24. Slide 24: Financial overview

    Financial overview Capitalization as of March 24, 2023 CASH POSITION as of December 31, 2022 $2.3M +$4.1M gross proceeds from ATM sales in Q1 2023 +$7.0M of SWK loan* gross proceeds in January 2023 +$2.7M of registered direct offering** gross proceeds in March 2023 Extends cash runway into middle of

  25. Slide 25: Thank You

    Thank You www.acertx.com

Acer Therapeutics — Investor Presentation (March 2023) on 6ix